ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Milano, Lombardia, ITA:

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis...

Enrolling
Multiple Sclerosis (MS)
Other: Ofatumumab placebo
Drug: Siponimod

Phase 3

Novartis
Novartis

Milano, MI, Italy and 73 other locations

This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Milano, Lombardia, Italy and 161 other locations

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Enrolling
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

Milano, MI, Italy and 107 other locations

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 in Participants With Multiple Sclerosis.

(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...

Enrolling
Multiple Sclerosis
Drug: RO7121932 - MAD
Drug: RO7121932 SC - SAD

Phase 1

Roche
Roche

Milano, Lombardia, Italy and 23 other locations

A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT (LemKids)

effects of alemtuzumab on other multiple sclerosis (MS) disease characteristics such as cognition and quality of life (Qo...

Active, not recruiting
Multiple Sclerosis
Drug: Beta-Interferon
Drug: Methylprednisolone

Phase 3

Genzyme
Genzyme

Milano, Italy and 20 other locations

A Study To Evaluate Safety And Efficacy Of Ocrelizumab In Comparison With Fingolimod In Children And Adolescents With Relapsing-Remitting Multiple Sclerosis (Operetta 2)

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Drug: Ocrelizumab

Phase 3

Roche
Roche

Milano, Lombardia, Italy and 120 other locations

Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS (STHENOS)

study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...

Enrolling
Multiple Sclerosis
Drug: Ofatumumab
Drug: First line DMT

Phase 3

Novartis
Novartis

Milano, MI, Italy and 49 other locations

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab (ARTIOS)

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Pavia, PV, Italy and 122 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Milano, MI, Italy and 211 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Pavia, PV, Italy and 229 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems